Initial assays could include in vitro enzymatic activity measurements to confirm inhibition of recombinant human SIRT4, followed by in vitro podocyte or proximal tubular cell models of diabetic nephropathy to assess its effects on mitochondrial function, ROS generation, and apoptosis. Here, SIRT4 is linked to diabetic kidney disease.